Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Precancerous Conditions 4Breast Neoplasms 4Neoplasms 2Adenomatous Polyposis Coli 2Unspecified Adult Solid Tumor, Protocol Specific 1Tobacco Use Disorder 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pain 1Melanoma 1Leukoplakia, Oral 1Inflammation 1Hypertension 1Desmoid Tumors 1Coproporphyria 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Cisplatin 136Radiotherapy 90Cetuximab 89pembrolizumab 65Fluorouracil 56Docetaxel 56Carboplatin 51Paclitaxel 44Radiotherapy, Intensity-Modulated 37Nivolumab 35durvalumab 19Erlotinib Hydrochloride 18Immunohistochemistry 16Radiation 13tremelimumab 12Gemcitabine 11Surgical Procedures, Operative 10Gene Expression Profiling 10Drug Therapy 10Biopsy 10Albumin-Bound Paclitaxel 10Chemotherapy, Adjuvant 9Capecitabine 9Bevacizumab 9atezolizumab 8Radiosurgery 8Polymerase Chain Reaction 8Neoadjuvant Therapy 8Ipilimumab 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Squamous Cell Carcinoma of Head and Neck × Sulindac × Clear all
NCT01515137 2023-03-28

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

University of Pittsburgh

Phase 1 Completed
47 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡